MSB 7.69% $1.19 mesoblast limited

banter and General Discussion, page-10127

  1. 1,733 Posts.
    lightbulb Created with Sketch. 182
    My understanding was that Gruber & Krause left FDA because Fed Administration authorised 6 month C19 booster after second shot without satisfying adequate FDA assessment procedure and evidence. I listen to an interesting podcast TWIVO (this week in virology) and recall similar sentiment from virology researchers at the time. You know, good science. I got the booster anyway. You know, age + risk and superstition.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.